CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 121 enrolled
Drug / intervention
Tranexamic Acid Injectable Product +1 moredrug
Likely dose
Tranexamic Acid Injectable Product 1 gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05397652
NCT05397652Phase 4Completed

Effect of Intravenously Administered Tranexamic Acid on Intraoperative Visual Clarity, Perioperative Blood Loss and Early Postoperative Outcomes in Shoulder Arthroscopy Performed in the Beach Chair Position: A Randomized Controlled Trial

Nikola Matejcic·interventional·Posted May 31, 2022·Updated Feb 24, 2026

In Brief

A Phase 4 clinical trial evaluating Tranexamic Acid Injectable Product and Placebo for Rotator Cuff Tears and 2 related conditions. Completed, enrolled 121 participants across 1 site.

Detailed Summary

Shoulder arthroscopy offers numerous advantages and has led to a continuous increase in procedural complexity. Adequate intraoperative visual clarity is essential for successful performance of the procedure and is primarily dependent on effective hemorrhage control.The aim of this prospective, double-blind, randomized controlled study is to evaluate the effect of intravenously administered tranexamic acid (TXA) on intraoperative visual clarity, perioperative blood loss, procedure duration, and early postoperative outcomes in patients undergoing shoulder arthroscopy in the beach chair position, an area for which limited data are currently available in the literature. In both the experimental and control groups, hemoglobin levels are measured in the irrigation fluid and in patients' blood samples obtained before and after surgery. Additional outcomes include intraoperative visual clarity, duration of the procedure, postoperative shoulder swelling, postoperative pain intensity, and analgesic consumption.This study applies established scientific methods to determine whether there is a justified basis for the introduction of TXA into routine clinical practice for shoulder arthroscopy.

Study Details

Timeline

Phase 4CompletedFinished
20222023202420252026
First PostedMay 31, 2022
Enrollment StartMay 24, 2021
Primary CompletionJul 21, 2023
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 4.1 years ago

Interventions

Tranexamic Acid Injectable Productdrug

Patients from the experimental group will receive 10 minutes before the procedure 1 g of tranexamic acid in 100 ml of saline intravenously unlike the patients in the control group who will receive just sterile saline.

Placebodrug

Patients from experimental group will receive 10 minutes before the procedure 1 g of tranexamic acid in 100 ml of saline intravenously unlike the patients in the control group who will receive just sterile saline.